Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Teppei Matsui

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Oncology Letters|December 19, 2013
Sustained complete response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: A case reportKazue Shiozawa, Manabu Watanabe, Takashi Ikehara, et al.
Clinical Journal of Gastroenterology|April 17, 2022
Usefulness of partial splenic embolization for left-sided portal hypertension in a patient with a pancreatic neuroendocrine neoplasm: a case report and review of the literatureTeppei Matsui, Hidenari Nagai, Makoto Amanuma, et al.
Clinical Cancer Drugs|September 6, 2016
The Importance of Lamivudine Therapy in Liver Cirrhosis Patients Related HBV with Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion ChemotherapyKoichi Momiyama, Hidenari Nagai, Yu Ogino, et al.
Case Reports in Oncology|December 19, 2014
Delayed intratumoral hemorrhage after drug-eluting bead transarterial chemoembolization for hepatocellular carcinomaKazue Shiozawa, Manabu Watanabe, Takashi Ikehara, et al.
Hepato-Gastroenterology|July 10, 2015
Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Propensity Score Matching StudyKazue Shiozawa, Manabu Watanabe, Takashi Ikehara, et al.
Cancer Chemotherapy and Pharmacology|February 25, 2010
Hepatotoxicity of intra-arterial combination chemotherapy in patients with liver cirrhosis and advanced hepatocellular carcinomaHidenari Nagai, Teppei Matsui, Masahiro Kanayama, et al.
Hepato-Gastroenterology|July 16, 2015
Host Immunity Influences the Efficacy of Combined Intra-Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in Liver Cirrhosis PatientsHidenari Nagai, Takanori Mukouzu, Daigo Matsui, et al.
Cancer Chemotherapy and Pharmacology|November 14, 2013
Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenibHidenari Nagai, Takenori Kanekawa, Kojiro Kobayashi, et al.
Anticancer Research|February 27, 2026
Clinical Utility of Tremelimumab/Durvalumab as First-line Treatment for Unresectable Hepatocellular Carcinoma: Serum Cytokine Profile InsightsKunihide Mohri, Hidenari Nagai, Takanori Mukozu, et al.
Oncology|September 12, 2024
The Usefulness of Serum Interleukin-6 as a Predictor of Response to Atezolizumab plus Bevacizumab Combination Treatment in Hepatocellular CarcinomaTakanori Mukozu, Hidenari Nagai, Hideki Nagumo, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Oncology Letters|December 19, 2013
Sustained complete response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: A case reportKazue Shiozawa, Manabu Watanabe, Takashi Ikehara, et al.
Clinical Journal of Gastroenterology|April 17, 2022
Usefulness of partial splenic embolization for left-sided portal hypertension in a patient with a pancreatic neuroendocrine neoplasm: a case report and review of the literatureTeppei Matsui, Hidenari Nagai, Makoto Amanuma, et al.
Clinical Cancer Drugs|September 6, 2016
The Importance of Lamivudine Therapy in Liver Cirrhosis Patients Related HBV with Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion ChemotherapyKoichi Momiyama, Hidenari Nagai, Yu Ogino, et al.
Case Reports in Oncology|December 19, 2014
Delayed intratumoral hemorrhage after drug-eluting bead transarterial chemoembolization for hepatocellular carcinomaKazue Shiozawa, Manabu Watanabe, Takashi Ikehara, et al.
Hepato-Gastroenterology|July 10, 2015
Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Propensity Score Matching StudyKazue Shiozawa, Manabu Watanabe, Takashi Ikehara, et al.
Cancer Chemotherapy and Pharmacology|February 25, 2010
Hepatotoxicity of intra-arterial combination chemotherapy in patients with liver cirrhosis and advanced hepatocellular carcinomaHidenari Nagai, Teppei Matsui, Masahiro Kanayama, et al.
Hepato-Gastroenterology|July 16, 2015
Host Immunity Influences the Efficacy of Combined Intra-Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in Liver Cirrhosis PatientsHidenari Nagai, Takanori Mukouzu, Daigo Matsui, et al.
Cancer Chemotherapy and Pharmacology|November 14, 2013
Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenibHidenari Nagai, Takenori Kanekawa, Kojiro Kobayashi, et al.
Anticancer Research|February 27, 2026
Clinical Utility of Tremelimumab/Durvalumab as First-line Treatment for Unresectable Hepatocellular Carcinoma: Serum Cytokine Profile InsightsKunihide Mohri, Hidenari Nagai, Takanori Mukozu, et al.
Oncology|September 12, 2024
The Usefulness of Serum Interleukin-6 as a Predictor of Response to Atezolizumab plus Bevacizumab Combination Treatment in Hepatocellular CarcinomaTakanori Mukozu, Hidenari Nagai, Hideki Nagumo, et al.
Pageof 7